Oscotec to Earn $38 Million from Sanofi's Licensing of Alzheimer's Candidate

MT Newswires Live12-16

Oscotec (KOSDAQ:A039200) will receive an upfront payment and future milestone payments, totaling $37.6 million or 55.3 billion South Korean won, after signing a deal to license Sanofi the Alzheimer's treatment candidate ADEL-Y01 from its joint developer, Adele.

The contract amount is based on a 47% revenue share and conditional on the success of clinical trials, regulatory approval, and the commercialization of the drug.

The global licensing deal includes ongoing royalty payments based on net sales if the product reaches the market.

However, the contract may be terminated if development or regulatory approval is unsuccessful, with no obligation for Oscotec to return funds.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2591607432?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-16 17:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2591607432","market":"nz","top_or_hot":-1,"title":"Oscotec to Earn $38 Million from Sanofi's Licensing of Alzheimer's Candidate","media":"MT Newswires Live","content":"<html><body><p> Oscotec (KOSDAQ:A039200) will receive an upfront payment and future milestone payments, totaling $37.6 million or 55.3 billion South Korean won, after signing a deal to license <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> the Alzheimer's treatment candidate ADEL-Y01 from its joint developer, Adele.</p><p>The contract amount is based on a 47% revenue share and conditional on the success of clinical trials, regulatory approval, and the commercialization of the drug.</p><p>The global licensing deal includes ongoing royalty payments based on net sales if the product reaches the market.</p><p>However, the contract may be terminated if development or regulatory approval is unsuccessful, with no obligation for Oscotec to return funds.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Oscotec to Earn $38 Million from Sanofi's Licensing of Alzheimer's Candidate</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOscotec to Earn $38 Million from Sanofi's Licensing of Alzheimer's Candidate\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-16 17:11</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Oscotec (KOSDAQ:A039200) will receive an upfront payment and future milestone payments, totaling $37.6 million or 55.3 billion South Korean won, after signing a deal to license <a href=\"https://laohu8.com/S/GCVRZ\">Sanofi</a> the Alzheimer's treatment candidate ADEL-Y01 from its joint developer, Adele.</p><p>The contract amount is based on a 47% revenue share and conditional on the success of clinical trials, regulatory approval, and the commercialization of the drug.</p><p>The global licensing deal includes ongoing royalty payments based on net sales if the product reaches the market.</p><p>However, the contract may be terminated if development or regulatory approval is unsuccessful, with no obligation for Oscotec to return funds.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNYNF","symbol_name":"Sanofi","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2591607432","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2591607432","pubTimestamp":1765876274,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Oscotec  will receive an upfront payment and future milestone payments, totaling $37.6 million or 55.3 billion South Korean won, after signing a deal to license Sanofi the Alzheimer's treatment candidate ADEL-Y01 from its joint developer, Adele.The contract amount is based on a 47% revenue share and conditional on the success of clinical trials, regulatory approval, and the commercialization of the drug.The global licensing deal includes ongoing royalty payments based on net sales if the product reaches the market.However, the contract may be terminated if development or regulatory approval is unsuccessful, with no obligation for Oscotec to return funds.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNYNF":"Sanofi","BK4007":"制药"},"translate_title":"Oscotec将从赛诺菲阿尔茨海默病候选药物许可中赚取3800万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNYNF":1.5},"content_text":"Oscotec (KOSDAQ:A039200) will receive an upfront payment and future milestone payments, totaling $37.6 million or 55.3 billion South Korean won, after signing a deal to license Sanofi the Alzheimer's treatment candidate ADEL-Y01 from its joint developer, Adele.The contract amount is based on a 47% revenue share and conditional on the success of clinical trials, regulatory approval, and the commercialization of the drug.The global licensing deal includes ongoing royalty payments based on net sales if the product reaches the market.However, the contract may be terminated if development or regulatory approval is unsuccessful, with no obligation for Oscotec to return funds.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591607432","isCrawlerRequest":true}